All News
Filter News
Found 808,632 articles
-
Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
4/18/2024
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that the first patient has been dosed in the fourth cohort of its Phase 1/2 study of ONCT-534 for the treatment of patients with advanced prostate cancer who are relapsed or refractory to approved androgen receptor pathway inhibitors (ARPI).
-
Panasonic and Shinobi Therapeutics Partner to Develop Efficient and Cost-Effective iPS Cell Therapy Manufacturing Technology
4/18/2024
Shinobi Therapeutics today announced a partnership with Panasonic Holdings Corp and Kyoto University's Center for iPS Cell Research and Application (CiRA).
-
Immix Biopharma on Track to Dose NXC-201 Patients in United States
4/18/2024
Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amyloidosis and other autoimmune diseases, today announced that Immix Biopharma is on track to dose NXC-201 patients in the U.S. with no change in patient enrollment timing.
-
AIxMed and CorePlus Partner to study a Urine Cytology Workflow Solution
4/18/2024
AIxMed, innovators and providers of an AI-powered computational platform for cytology applications, and CorePlus a leader in precision pathology have entered into an agreement to conduct a pilot study applying the AIxMed's AI algorithm to test a workflow solution for urine cytology.
-
Ferring Pharmaceuticals and SK Pharmteco Enter into Commercial Gene Therapy Manufacturing Deal
4/18/2024
Ferring Pharmaceuticals and SK pharmteco today announced an agreement to scale up commercial manufacturing capacity for the drug substance of Ferring’s intravesical non-replicating gene therapy ADSTILADRIN (nadofaragene firadenovec-vncg) for ensuring long-term future supply.
-
GIE Medical Announces First Patient Enrolled in PATENT-B Benign Bowel Stricture Treatment Study
4/18/2024
GIE Medical, a clinical stage company developing solutions for patients suffering from benign stricture(s) of the esophagus or bowel, announced today that enrollment has begun in its Paclitaxel Coated Balloon for the Treatment of Chronic Benign Stricture - Bowel (PATENT-B) study.
-
FDA Approves Genentech's Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung Cancer
4/18/2024
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Alecensa® (alectinib) for adjuvant treatment following tumor resection for patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) (tumors ≥ 4 cm or node positive), as detected by an FDA-approved test.
-
New Study from HSS Reveals Minimally Invasive Procedure Can Delay Arthritis in Select Patients with Hip Impingement
4/18/2024
A new study by surgeon-scientists at Hospital for Special Surgery (HSS) found that 25% of patients with hip impingement who underwent modern arthroscopy for their condition experienced a delay in the natural progression of osteoarthritis.
-
AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per Share
4/18/2024
ABVC BioPharma, Inc and Oncology/Hematology, announced today that the Company's subsidiary AiBtl BioPharma Inc. acquired TT Life Company, an established player in the precision medicine industry.
-
Intra-Cellular Therapies Prices Public Offering of Common Stock - April 18, 2024
4/18/2024
Intra-Cellular Therapies, Inc. announced the pricing of its previously announced underwritten public offering of 6,849,316 shares of its common stock at a public offering price of $73.00 per share.
-
Zura Bio Announces Oversubscribed $112.5 Million Private Placement
4/18/2024
Zura Bio Limited today announced that it has entered into subscription agreements for a private placement that is expected to result in gross proceeds of approximately $112.5 million, before deducting placement agent fees and offering expenses (the “Private Placement”).
-
Nexcella, an Immix Biopharma Subsidiary, on Track to Dose NXC-201 Patients in United States
4/18/2024
Nexcella today announced that it is on track to dose NXC-201 patients in the U.S. with no change in patient enrollment timing.
-
Texas Biomed researching vaccines and treatments for highly pathogenic avian influenza
4/18/2024
Researchers at Texas Biomedical Research Institute (Texas Biomed) are studying potential vaccines, antivirals and antibodies against highly pathogenic avian influenza, including H5N1 strains that closely mirror the one recently detected in cows, chickens and one person in Texas.
-
RenovoRx Regains Compliance with Nasdaq Stockholders’ Equity Requirement
4/18/2024
RenovoRx, Inc. announced that, in light of its recent successful fundraising activity, it has received written confirmation from The Nasdaq Stock Market LLC that the Company has regained compliance with the $2.5 million minimum stockholders’ equity requirement in Nasdaq Listing Rule 5550.
-
GE HealthCare Introduces AI-Enhanced Voluson Signature 20 and 18 Ultrasound Systems to Advance Women’s Health Imaging
4/18/2024
GE HealthCare announced the launch of the Voluson Signature 20 and 18 ultrasound systems, which comprehensively integrate artificial intelligence, advanced tools and an ergonomic design to speed exam time for clinicians while delivering a clearer picture of various conditions impacting women’s health.
-
Denis Johnson Joins Kindeva Drug Delivery as Chief Operating Officer to Lead Global Operations
4/18/2024
Kindeva Drug Delivery, a global leader in drug-device combination products, announced that Denis Johnson has joined the company as its new Chief Operating Officer.
-
Renovaro Inc. Proudly Announces the Appointment Of Professor Dr. Geert Kazemier as the Chairman of its Scientific Advisory Board
4/18/2024
Renovaro Inc., a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, announces the distinguished Professor Geert Kazemier, MD, PhD, as the new Chairman of its Scientific Advisory Board.
-
Novel cell therapy treatments offer promise to immune-compromised children
4/18/2024
In a first-of-its-kind clinical trial, researchers found that intravenous therapies made from virus-specific T-cells can effectively treat immunocompromised pediatric patients, far surpassing the current standard of care, according to new research published in Nature Communications.
-
Agitated Solutions Receives Health Canada License for Orbis Microbubble Generator to Streamline Cardiac Bubble Studies
4/18/2024
Agitated Solutions, Incorporated announced that it has been issued a Medical Device Establishment License from Health Canada for its innovative Orbis™ Microbubble Generator that simplifies and streamlines the process of saline agitation and delivery for cardiac bubble studies.
-
Precision Optics Announces Receipt of $720,000 Follow-On Production Order from Top Tier Defense/Aerospace Customer for New Optical Application
4/18/2024
Precision Optics Corporation, Inc. announced it has received a $720,000 follow on production order from a top tier defense/aerospace company addressing a commercial application that leverages the Company's proprietary manufacturing technology developed for high precision micro-optics systems.